Who will pay $93,000 for Provenge, Dendreon (DNDN)'s new vaccine-based treatment for advanced prostate cancer? The answer is you. And me. The taxpayer. The drug is perfectly designed to extract as ...

Shares in Dendreon, maker of the prostate cancer cell therapy Provenge, are down 10% in morning trading as the Centers for Medicare and Medicaid Services begin a 12-month process to decide in what ...

Data from the studies revealed that Provenge treatment results in antigen spread associated with overall survival benefits. Moreover, Dendreon presented data from the phase IV PROCEED study on ...

Provenge, a treatment that trains immune cells to attack a cancer, would be revolutionary even if there were nothing to it but cool science. But the way it has been studied, the hurdles it is still ...

If a cancer drug can prolong some poor man's life by 4 months, should 93,000 of your tax dollars be spent on it? How about 93,000 of your insurance dollars? That's what Dendreon's PROVENGE does, and ...

Dendreon's IMPACT study of its cancer vaccine Provenge beat the FDA's 22 percent "reduction in risk of death" standard by just half a percent: The company said it reduced "risk of death" by 22.5 ...

Much has been said and written about the circumstances surrounding the launch of Dendreon’s innovation in cancer treatment, Provenge, a novel immunotherapeutic treatment for end-stage prostate cancer.

May 3, 2010 — Clinicians are likely to be hearing from patients about sipuleucel-T (Provenge, Dendreon), the immunotherapy that has just been approved by the US Food and Drug Administration (FDA) for ...

Centre Street, the historic main artery of Fernandina Beach, feels more like a storybook village than a typical downtown. Read full article: Discover the heart of Fernandina Beach on Centre Street ...

The European Commission (EC) has recently granted marketing authorization for Dendreon Corporation’s (DNDN) Provenge. The drug is approved in the EU for the treatment of asymptomatic or minimally ...

Biotechnology company Dendreon said Wednesday that sales of its prostate cancer drug Provenge continued to climb in the third quarter, although Dendreon took a larger loss as it built up its ...

The search for prostate cancer treatments is filled with prospects and littered with failures. Sprycel is being tested against prostate cancer in combination with Taxotere (from sanofi-aventis ...